What Is Cannabigerolic Acid (CBGA)?
Cannabigerolic acid (CBGA) is the acidic, non-decarboxylated form of cannabigerol (CBG) and the central biosynthetic intermediate in the Cannabis sativa cannabinoid pathway. It is the molecule from which the plant produces the acidic forms of THC, CBD, and CBC, which is why CBGA is sometimes referred to as the “mother cannabinoid” or “stem cannabinoid” (Gagne et al., 2012; Luo et al., 2019).
Unlike CBG, which has been the subject of a growing number of pharmacology studies, CBGA itself remains an emerging area of research. Most peer-reviewed work on CBGA falls into three categories: enzymology and biosynthesis, in vitro receptor and channel pharmacology, and a small but expanding set of preclinical disease models. This article summarizes what is currently known and where the literature is still thin.
Biosynthesis: Why CBGA Matters
CBGA is the first cannabinoid that the cannabis plant produces de novo. The classical pathway, described in detail by Sirikantaramas et al. (2004), Gagne et al. (2012), and later Luo et al. (2019), runs as follows:
1. The fatty-acid–derived precursor olivetolic acid is produced by the polyketide-pathway enzyme olivetolic acid cyclase, working with a tetraketide synthase (Gagne et al., 2012). 2. The terpenoid-pathway intermediate geranyl pyrophosphate (GPP) is generated through the methylerythritol phosphate (MEP) pathway in trichome cells. 3. The enzyme CBGA synthase (an aromatic prenyltransferase, sometimes called geranyl diphosphate:olivetolate geranyltransferase) joins olivetolic acid and GPP to form CBGA (Page & Boubakir, 2014).
From CBGA, three competing oxidative-cyclization enzymes — THCA synthase, CBDA synthase, and CBCA synthase — convert CBGA into the acidic forms of THC, CBD, and CBC respectively (Sirikantaramas et al., 2004; Taura et al., 2007). Whatever CBGA is not enzymatically converted in the trichome remains as CBGA, which can later decarboxylate into CBG when exposed to heat, light, or extended time.
This central position in the biosynthetic network explains both why CBGA is scarce in fully mature, high-THC plants (most of it has been consumed) and why interest in CBGA-rich chemovars has increased: harvesting the plant earlier, or breeding for low THCA/CBDA synthase activity, allows growers to retain more CBGA in the final flower.
Pharmacology of CBGA
The pharmacology of CBGA is still being mapped, and most of what is known comes from in vitro work. The major targets reported to date include:
PPAR-α and PPAR-γ. CBGA has been reported to act as a dual peroxisome proliferator-activated receptor (PPAR) α/γ agonist (D’Aniello et al., 2019). PPAR-α is a key regulator of lipid metabolism, while PPAR-γ is involved in glucose homeostasis and adipocyte differentiation, and dual agonists are studied as potential candidates for metabolic syndrome and type 2 diabetes.
TRP channels. Like CBG, CBGA interacts with several transient receptor potential (TRP) channels. Of particular note, CBGA has been reported as a potent inhibitor of TRPM7 — an ion channel and atypical kinase implicated in inflammation, cardiovascular function, and cancer cell proliferation (Mahmoudinoodezh et al., 2024). The same study found that CBGA’s TRPM7 inhibition required a functional kinase domain on the channel.
Cholinesterases and BACE-1. A 2024 in vitro and in silico study identified CBGA (alongside CBDA) as a multi-target inhibitor of acetylcholinesterase, butyrylcholinesterase, and β-secretase-1 (BACE-1) — three enzymes implicated in Alzheimer’s disease pathology (Antognoni et al., 2024). The study reported activity in cellular and Drosophila models but did not extend to mammalian disease models.
Cannabinoid receptors. CBGA’s affinity for the classical cannabinoid receptors CB1 and CB2 is generally reported as low. Like other cannabinoid acids, it does not produce intoxicating effects.
The breadth of these targets — ion channels, nuclear receptors, hydrolases — makes CBGA a clear example of a polypharmacological compound, but it also means that mechanistic claims for any particular outcome should be interpreted cautiously.
Notable Preclinical Research
SARS-CoV-2 spike-protein binding
The most widely publicized CBGA study to date is van Breemen et al. (2022), published in the Journal of Natural Products. Using affinity-selection mass spectrometry, the researchers identified CBGA and CBDA as ligands for the SARS-CoV-2 spike protein. In follow-up cell-based assays, both acids prevented entry of a SARS-CoV-2 spike pseudovirus into human epithelial cells and blocked infection by live SARS-CoV-2, including the alpha (B.1.1.7) and beta (B.1.351) variants.
These are in vitro results obtained at concentrations achievable in cell culture, not in the human bloodstream. The authors explicitly cautioned that the work does not establish CBGA as a treatment or preventive for COVID-19 in humans, and no peer-reviewed clinical trial has tested that hypothesis. The study is best understood as a hypothesis-generating finding that motivated subsequent (still ongoing) research into cannabinoid-acid antivirals.
Anticonvulsant activity
In a 2021 study by Anderson and colleagues, CBGA was tested in mouse models of generalized epilepsy and Dravet syndrome. The study reported that CBGA showed anticonvulsant activity at higher doses but produced pro-convulsant effects at certain dose combinations and enhanced the anticonvulsant effect of clobazam (Anderson et al., 2021). The authors concluded that the dose–response profile is complex and that pharmacokinetic interactions need to be carefully characterized before any therapeutic claims could be made.
Metabolic effects
D’Aniello et al. (2019) and subsequent work have explored CBGA’s PPAR-α/γ activity in the context of metabolic disease. In cellular models, CBGA influenced markers of lipid storage and glucose handling consistent with PPAR engagement. These findings remain at the preclinical, mechanism-of-action stage.
Other areas
Smaller bodies of work have investigated CBGA in cardiomyocyte models of arrhythmia, in cancer cell lines (often as a comparator to CBG), and as a component of full-spectrum hemp extracts. Reviews by Calapai et al. (2022) and a 2025 update on acidic cannabinoid pharmacology summarize this scattered literature and consistently note the same limitation: the translational gap between in vitro findings and human clinical evidence is substantial.
Stability: Why CBGA Doesn’t Stay CBGA
CBGA is a thermally and photochemically labile molecule. When cannabis flower is heated, smoked, vaporized, or stored for extended periods, CBGA gradually loses its carboxyl group through decarboxylation and converts into CBG. This is the same process that converts THCA into THC.
For consumers and researchers, this has practical implications:
- Products labeled as CBGA-rich must be stored cool and protected from light to retain their CBGA content.
- Lab analyses sometimes report combined “total CBG” (CBGA + CBG after decarboxylation) values rather than separating the two, which can make label comparisons difficult.
- Preclinical studies that heat-treat or solubilize CBGA in certain solvents may produce mixtures whose pharmacology reflects both CBGA and CBG.
Human Data
Direct clinical data on isolated CBGA in humans are essentially absent at the time of writing. There are no published randomized controlled trials of CBGA monotherapy for any condition. Available human-relevant evidence is limited to pharmacokinetic observations from full-spectrum hemp products containing CBGA among other cannabinoids and some survey-level reports of self-medication with CBGA-rich products.
This is an important caveat. The widely shared media coverage of the van Breemen et al. (2022) paper frequently outpaced the actual evidence, and several public-health agencies subsequently issued statements clarifying that the in vitro findings did not establish CBGA as a clinically validated antiviral.
Safety and Practical Considerations
CBGA has not been associated with intoxication in any controlled study. Acute safety data in humans, however, are limited to incidental observations from full-spectrum cannabinoid products. Several practical considerations apply:
- Drug-metabolism interactions. Cannabinoid acids, including CBGA, have been reported to inhibit cytochrome P450 enzymes in vitro (Nasrin et al., 2021), which could affect the metabolism of certain prescription medications.
- Pregnancy and breastfeeding. No human safety data exist; CBGA-containing products should be avoided.
- Product variability. Independent testing of cannabinoid products has repeatedly identified discrepancies between labeled and measured cannabinoid content (Bonn-Miller et al., 2017). Verifying with a current third-party Certificate of Analysis is advisable.
- Regulatory status. The U.S. Food and Drug Administration has not approved CBGA for the treatment, prevention, cure, or diagnosis of any medical condition.
Anyone considering CBGA-containing products — particularly alongside prescription medications, or in the context of a health condition — should speak with a qualified medical professional first.
Frequently Asked Questions
Is CBGA the same as CBG?
No. CBGA is the acidic precursor; CBG is the decarboxylated, neutral form. Heat, light, and time gradually convert CBGA into CBG. Some studies report effects unique to the acid form (such as CBGA’s PPAR-α/γ activity), so they should not be assumed to be interchangeable in research contexts (D’Aniello et al., 2019; Mahmoudinoodezh et al., 2024).
Does CBGA get you high?
The peer-reviewed literature does not describe CBGA as intoxicating. It has low affinity for CB1 receptors and has not produced THC-like effects in published research models.
Can CBGA prevent or treat COVID-19?
No clinical trial has tested this. The van Breemen et al. (2022) study showed CBGA could block spike-protein–mediated cellular entry in cell culture. That is a long way from a validated treatment in humans, and the authors themselves emphasized this distinction.
Why is CBGA called the “mother cannabinoid”?
Because it is the biosynthetic precursor that the cannabis plant uses to produce the acidic forms of THC, CBD, and CBC (Gagne et al., 2012). Most cannabinoids in mature plants ultimately trace back to CBGA.
Important Disclaimer
The information in this article is for educational purposes only and is not medical advice. Statements about cannabigerolic acid have not been evaluated by the U.S. Food and Drug Administration. CBGA-containing products are not intended to diagnose, treat, cure, or prevent any disease. Always consult a licensed physician or qualified healthcare provider before starting any new supplement, particularly if you are pregnant, nursing, taking prescription medications, or managing a chronic medical condition.
References
Anderson, L. L., Heblinski, M., Absalom, N. L., Hawkins, N. A., Bowen, M. T., Benson, M. J., Zhang, F., Bahceci, D., Doohan, P. T., Chebib, M., Kearney, J. A., McGregor, I. S., & Arnold, J. C. (2021). Cannabigerolic acid, a major biosynthetic precursor molecule in cannabis, exhibits divergent effects on seizures in mouse models of epilepsy. British Journal of Pharmacology, 178(24), 4826–4841. https://doi.org/10.1111/bph.15661
Antognoni, F., Lianza, M., Poli, F., Buccioni, M., Santinelli, C., Caprioli, G., & Iannarelli, R. (2024). Identification of cannabidiolic and cannabigerolic acids as multi-target-directed AChE, BuChE, and BACE-1 inhibitors against Alzheimer’s disease by in silico, in vitro, and in vivo studies. Molecules, 29(24), 5970. https://doi.org/10.3390/molecules29245970
Bonn-Miller, M. O., Loflin, M. J. E., Thomas, B. F., Marcu, J. P., Hyke, T., & Vandrey, R. (2017). Labeling accuracy of cannabidiol extracts sold online. JAMA, 318(17), 1708–1709. https://doi.org/10.1001/jama.2017.11909
Calapai, F., Cardia, L., Esposito, E., Ammendolia, I., Mondello, C., Lo Giudice, R., Gangemi, S., Calapai, G., & Mannucci, C. (2022). Pharmacological aspects and biological effects of cannabigerol and its synthetic derivatives. Evidence-Based Complementary and Alternative Medicine, 2022, 3336516. https://doi.org/10.1155/2022/3336516
D’Aniello, E., Fellous, T., Iannotti, F. A., Gentile, A., Allarà , M., Balestrieri, F., Gray, R., Amodeo, P., Vitale, R. M., & Di Marzo, V. (2019). Identification and characterization of phytocannabinoids as novel dual PPARα/γ agonists by a computational and in vitro experimental approach. Biochimica et Biophysica Acta (BBA) – General Subjects, 1863(3), 586–597. https://doi.org/10.1016/j.bbagen.2019.01.002
Gagne, S. J., Stout, J. M., Liu, E., Boubakir, Z., Clark, S. M., & Page, J. E. (2012). Identification of olivetolic acid cyclase from Cannabis sativa reveals a unique catalytic route to plant polyketides. Proceedings of the National Academy of Sciences, 109(31), 12811–12816. https://doi.org/10.1073/pnas.1200330109
Luo, X., Reiter, M. A., d’Espaux, L., Wong, J., Denby, C. M., Lechner, A., Zhang, Y., Grzybowski, A. T., Harth, S., Lin, W., Lee, H., Yu, C., Shin, J., Deng, K., Benites, V. T., Wang, G., Baidoo, E. E. K., Chen, Y., Dev, I., … Keasling, J. D. (2019). Complete biosynthesis of cannabinoids and their unnatural analogues in yeast. Nature, 567(7746), 123–126. https://doi.org/10.1038/s41586-019-0978-9
Mahmoudinoodezh, H., Telek, A., Brych, M., Wagner, M., Saliba, A. N., Schweigel-Röntgen, M., Krüger, J., Yew, K. K., Kirschner, J. P., Eickholt, B. J., & Zierler, S. (2024). Cannabigerolic acid (CBGA) inhibits the TRPM7 ion channel through its kinase domain. Function, 5(1), zqad069. https://doi.org/10.1093/function/zqad069
Nasrin, S., Watson, C. J. W., Perez-Paramo, Y. X., & Lazarus, P. (2021). Cannabinoid metabolites as inhibitors of major hepatic CYP450 enzymes, with implications for cannabis–drug interactions. Drug Metabolism and Disposition, 49(12), 1070–1080. https://doi.org/10.1124/dmd.121.000442
Page, J. E., & Boubakir, Z. (2014). Aromatic prenyltransferase from Cannabis (U.S. Patent No. 8,884,100). U.S. Patent and Trademark Office.
Sirikantaramas, S., Morimoto, S., Shoyama, Y., Ishikawa, Y., Wada, Y., Shoyama, Y., & Taura, F. (2004). The gene controlling marijuana psychoactivity: Molecular cloning and heterologous expression of Δ¹-tetrahydrocannabinolic acid synthase from Cannabis sativa L. Journal of Biological Chemistry, 279(38), 39767–39774. https://doi.org/10.1074/jbc.M403693200
Taura, F., Sirikantaramas, S., Shoyama, Y., Yoshikai, K., Shoyama, Y., & Morimoto, S. (2007). Cannabidiolic-acid synthase, the chemotype-determining enzyme in the fiber-type Cannabis sativa. FEBS Letters, 581(16), 2929–2934. https://doi.org/10.1016/j.febslet.2007.05.043
van Breemen, R. B., Muchiri, R. N., Bates, T. A., Weinstein, J. B., Leier, H. C., Farley, S., & Tafesse, F. G. (2022). Cannabinoids block cellular entry of SARS-CoV-2 and the emerging variants. Journal of Natural Products, 85(1), 176–184. https://doi.org/10.1021/acs.jnatprod.1c00946
